Clinwright16.2.7
Listing of Treatment-Emergent Adverse Events
Made 2026-10-17 from simulated data.
ONCO-EX
Listing 16.2.7
Listing of Treatment-Emergent Adverse Events
Safety Analysis Set
| Subject | Treatment | System organ class | Preferred term | Start date | Severity | Serious | Outcome |
|---|---|---|---|---|---|---|---|
| ONCO-EX-701002 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 16FEB2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701002 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 25MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701002 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 04JUN2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701002 | Standard of Care | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 11JUL2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-701002 | Standard of Care | INVESTIGATIONS | HEART RATE INCREASED | 04NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701003 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | ARTHRITIS | 16APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 08JUN2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701004 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | ARTHRITIS | 27JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701004 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 12DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701004 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN ODOUR ABNORMAL | 18DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 05FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701005 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 03JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701005 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | PAROSMIA | 03DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701005 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | SYNCOPE | 11FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701007 | Standard of Care | INVESTIGATIONS | ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED | 05JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701007 | Standard of Care | INVESTIGATIONS | HEART RATE IRREGULAR | 24SEP2022 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701007 | Standard of Care | PSYCHIATRIC DISORDERS | DISORIENTATION | 10JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701008 | Clinwrightinib 200 mg | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 29MAY2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701008 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 05JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701008 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 07JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 22JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 13AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701008 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701008 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 13SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701009 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 02MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701009 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 07MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701009 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 09MAY2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701009 | Clinwrightinib 200 mg | REPRODUCTIVE SYSTEM AND BREAST DISORDERS | BENIGN PROSTATIC HYPERPLASIA | 11JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 17NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701009 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 17NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701010 | Clinwrightinib 200 mg | INVESTIGATIONS | BIOPSY PROSTATE | 14JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701010 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 16JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 17JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701010 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | MUSCLE SPASMS | 19OCT2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-701010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 11NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 27NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701010 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH MACULO-PAPULAR | 28MAR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701010 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 19APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701011 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 02JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701012 | Standard of Care | INVESTIGATIONS | BLOOD CREATINE PHOSPHOKINASE INCREASED | 03OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701012 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 16OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701014 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FIBRILLATION | 23AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701014 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | PRODUCTIVE COUGH | 27NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701014 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 03JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701014 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 24APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701015 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 15JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701015 | Clinwrightinib 200 mg | INVESTIGATIONS | WEIGHT DECREASED | 02OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701015 | Clinwrightinib 200 mg | METABOLISM AND NUTRITION DISORDERS | DECREASED APPETITE | 05OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701015 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 25NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 12DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701015 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | PHARYNGEAL ERYTHEMA | 16JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701016 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 11SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701016 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 01NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701016 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 05JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701017 | Standard of Care | CARDIAC DISORDERS | BRADYCARDIA | 08AUG2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701017 | Standard of Care | INVESTIGATIONS | HEART RATE IRREGULAR | 17AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701017 | Standard of Care | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 19AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701017 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 19AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701018 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 05AUG2022 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701018 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 14AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701018 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | URTICARIA | 27OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701018 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 29OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701020 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 04SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701020 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 06SEP2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701020 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FEELING ABNORMAL | 17SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701020 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 27SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701021 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 06AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701021 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 06SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701021 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 11SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701021 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | URTICARIA | 12SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701022 | Standard of Care | PSYCHIATRIC DISORDERS | CONFUSIONAL STATE | 17AUG2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-701022 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | ARTHRALGIA | 10JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701022 | Standard of Care | REPRODUCTIVE SYSTEM AND BREAST DISORDERS | BENIGN PROSTATIC HYPERPLASIA | 08MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701022 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 22MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701023 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 03AUG2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-701023 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 07AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701024 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 04SEP2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701024 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | HIP FRACTURE | 06OCT2022 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701024 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 06OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701024 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 07OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701024 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | DECREASED APPETITE | 17OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701025 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 22SEP2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701025 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 25SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701025 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 01OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701025 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FIBRILLATION | 06DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701025 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | URINARY TRACT INFECTION | 07DEC2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701025 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 23MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701025 | Clinwrightinib 200 mg | SOCIAL CIRCUMSTANCES | ALCOHOL USE | 04APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701025 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | SOMNOLENCE | 16APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701025 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 17APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701026 | Clinwrightinib 200 mg | NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) | PROSTATE CANCER | 12SEP2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-701026 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 12DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701026 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 29JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701026 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 27APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701026 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS GENERALISED | 10MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701026 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHILLS | 14MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701026 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | ARTHRALGIA | 15MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701027 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 10NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701027 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 11DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701027 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | BLISTER | 15MAY2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701027 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 25MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701028 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 18OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701028 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 21OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701028 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 17DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701028 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 25MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701029 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 10OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701029 | Standard of Care | PSYCHIATRIC DISORDERS | COMPLETED SUICIDE | 12NOV2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-701029 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 14NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701029 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 22NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701029 | Standard of Care | INFECTIONS AND INFESTATIONS | GASTROENTERITIS VIRAL | 13JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701029 | Standard of Care | RENAL AND URINARY DISORDERS | POLLAKIURIA | 26FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701029 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 18MAR2023 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701031 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 29OCT2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701031 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE SWELLING | 25NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701031 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 04APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701031 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 10APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701034 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 26NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701035 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 18MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701036 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 25NOV2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-701036 | Standard of Care | GASTROINTESTINAL DISORDERS | VOMITING | 06DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701036 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | DYSPNOEA | 11DEC2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701036 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 24DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701038 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | FLANK PAIN | 12DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701038 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | CYSTITIS | 23DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701038 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 28JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701038 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | GASTROINTESTINAL HAEMORRHAGE | 04FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701038 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 18MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701038 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 12APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701038 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | DELIRIUM | 16MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701039 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | EMPHYSEMA | 31JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701039 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | DRUG ERUPTION | 21FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701039 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 27FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701039 | Standard of Care | PSYCHIATRIC DISORDERS | INSOMNIA | 27JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701039 | Standard of Care | PSYCHIATRIC DISORDERS | AGITATION | 25AUG2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701040 | Clinwrightinib 200 mg | NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) | PROSTATE CANCER | 11JAN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701040 | Clinwrightinib 200 mg | VASCULAR DISORDERS | HYPERTENSION | 24JAN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701040 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 30JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701040 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 31JAN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701040 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 01FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701040 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 19FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701040 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 21FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701041 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 05FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701041 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 08MAR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701041 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 25JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701041 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | DIARRHOEA | 31DEC2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701042 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 21FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701042 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 16MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701043 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 15MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701043 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 15MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701043 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE REACTION | 26MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701043 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 21JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701044 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 31MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701044 | Standard of Care | NERVOUS SYSTEM DISORDERS | SOMNOLENCE | 22APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701045 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 27MAR2023 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701045 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 06APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701045 | Standard of Care | GASTROINTESTINAL DISORDERS | GASTROOESOPHAGEAL REFLUX DISEASE | 22APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701047 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | ASTHENIA | 26JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701047 | Standard of Care | EYE DISORDERS | CONJUNCTIVITIS | 23AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701047 | Standard of Care | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 24OCT2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701048 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 08JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701048 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 19JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701048 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 29AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701048 | Clinwrightinib 200 mg | EYE DISORDERS | VISION BLURRED | 16OCT2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701049 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 02JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701049 | Standard of Care | VASCULAR DISORDERS | HYPOTENSION | 17AUG2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701049 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 17AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701051 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 01JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701051 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SUPRAVENTRICULAR EXTRASYSTOLES | 12JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701051 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 22JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701051 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 23SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701051 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 21NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701051 | Clinwrightinib 200 mg | EYE DISORDERS | VISION BLURRED | 13DEC2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701052 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PAIN | 19OCT2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701052 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 27OCT2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-701052 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 23NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701052 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 14DEC2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701052 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 03FEB2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701054 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | INFLUENZA | 26JUN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701055 | Standard of Care | GASTROINTESTINAL DISORDERS | FLATULENCE | 17JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701055 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 11JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701055 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 11JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701055 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | BACK PAIN | 14JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701055 | Standard of Care | CARDIAC DISORDERS | TACHYCARDIA | 16JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701055 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHILLS | 21JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701057 | Standard of Care | PSYCHIATRIC DISORDERS | IRRITABILITY | 22JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701057 | Standard of Care | VASCULAR DISORDERS | ORTHOSTATIC HYPOTENSION | 28JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-701057 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 29JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701057 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 30JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-701057 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 10AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-702001 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 22JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-702001 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH PAPULAR | 24JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-702001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 02JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-702001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | PYREXIA | 04JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-702001 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 11JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-702001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 26JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703001 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | ASTHENIA | 14JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703001 | Standard of Care | PSYCHIATRIC DISORDERS | CONFUSIONAL STATE | 14JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703001 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | SHOULDER PAIN | 22JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703001 | Standard of Care | GASTROINTESTINAL DISORDERS | VOMITING | 01JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703001 | Standard of Care | PSYCHIATRIC DISORDERS | INSOMNIA | 13JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703002 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 28MAR2022 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703002 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | SYNCOPE VASOVAGAL | 08MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703002 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 14JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703002 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FLUTTER | 30AUG2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-703002 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 20SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703002 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 09OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703003 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 23MAR2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703003 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SUPRAVENTRICULAR EXTRASYSTOLES | 28MAR2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703003 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 29MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703003 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 30MAR2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703003 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 05APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703003 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 07APR2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703003 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | SALIVARY HYPERSECRETION | 09APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703004 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 30APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703004 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 24SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 30MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | CONGENITAL, FAMILIAL AND GENETIC DISORDERS | VENTRICULAR SEPTAL DEFECT | 30JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | LIBIDO DECREASED | 01JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | DIARRHOEA | 17JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 17JUL2022 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | CARDIAC DISORDERS | CARDIAC DISORDER | 06AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 13AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 14AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FLUTTER | 04SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DISCHARGE | 11SEP2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | ABDOMINAL PAIN | 09OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 18OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 03NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703005 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | FACIAL BONES FRACTURE | 16NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703006 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 13JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703006 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | FLANK PAIN | 26JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703006 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | BLISTER | 22AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703006 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HYPERSOMNIA | 30SEP2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703006 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FIBRILLATION | 23OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703006 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 13NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703006 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 26JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703007 | Standard of Care | GASTROINTESTINAL DISORDERS | HIATUS HERNIA | 03JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703007 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | PYREXIA | 09JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703007 | Standard of Care | PSYCHIATRIC DISORDERS | DELUSION | 05AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703007 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 08SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703007 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 08NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703008 | Standard of Care | NERVOUS SYSTEM DISORDERS | SOMNOLENCE | 21NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703008 | Standard of Care | INFECTIONS AND INFESTATIONS | EAR INFECTION | 16DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703008 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 28DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703008 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 08JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703008 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 23FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 31AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703009 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 16SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703009 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 17OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703009 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | COGNITIVE DISORDER | 30OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703009 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 09FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703009 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | LIBIDO DECREASED | 15FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 17FEB2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-703011 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 25OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703012 | Standard of Care | GASTROINTESTINAL DISORDERS | HIATUS HERNIA | 24NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703012 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 14DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703013 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 08NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703016 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 10JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703016 | Standard of Care | INFECTIONS AND INFESTATIONS | URINARY TRACT INFECTION | 05APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703016 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHILLS | 07MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703016 | Standard of Care | GASTROINTESTINAL DISORDERS | NAUSEA | 06JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703016 | Standard of Care | INVESTIGATIONS | ELECTROCARDIOGRAM T WAVE INVERSION | 06JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703017 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 01JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703017 | Standard of Care | INFECTIONS AND INFESTATIONS | CYSTITIS | 04JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703017 | Standard of Care | INVESTIGATIONS | HEART RATE IRREGULAR | 06FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703018 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | COLD SWEAT | 14DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703018 | Standard of Care | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 23JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703020 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 17MAY2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-703020 | Clinwrightinib 200 mg | INVESTIGATIONS | WEIGHT DECREASED | 08JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703020 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 07AUG2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-703020 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 29SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703020 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 01NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703020 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 10NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703021 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHEST DISCOMFORT | 30MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703021 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 30MAR2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-703021 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | HALLUCINATION, VISUAL | 04APR2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-703021 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 10APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703021 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 19APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703022 | Standard of Care | NERVOUS SYSTEM DISORDERS | DIZZINESS | 05MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703023 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 22APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703023 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 12MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703024 | Standard of Care | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 05APR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703024 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | EXCORIATION | 10APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703024 | Standard of Care | EYE DISORDERS | CONJUNCTIVITIS | 03MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703025 | Clinwrightinib 200 mg | RENAL AND URINARY DISORDERS | CALCULUS URETHRAL | 04JUN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703025 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 11AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-703025 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 09OCT2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703025 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 21JAN2024 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-703030 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 26JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-703030 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 05JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-703030 | Standard of Care | NERVOUS SYSTEM DISORDERS | PSYCHOMOTOR HYPERACTIVITY | 11AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704001 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 12MAR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704001 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 18MAR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704001 | Clinwrightinib 200 mg | INVESTIGATIONS | BLOOD GLUCOSE INCREASED | 20MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 13MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704001 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | BLISTER | 15SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704001 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 29SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704001 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | PRODUCTIVE COUGH | 07DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704001 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 02JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704002 | Clinwrightinib 200 mg | CONGENITAL, FAMILIAL AND GENETIC DISORDERS | VENTRICULAR SEPTAL DEFECT | 01APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704002 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 08APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704002 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 22APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704002 | Clinwrightinib 200 mg | IMMUNE SYSTEM DISORDERS | SEASONAL ALLERGY | 03AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704002 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 18AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704002 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 17SEP2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704002 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 21NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704002 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE URTICARIA | 27DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704003 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE INDURATION | 15APR2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-704003 | Standard of Care | INFECTIONS AND INFESTATIONS | EAR INFECTION | 25APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704003 | Standard of Care | INFECTIONS AND INFESTATIONS | INFLUENZA | 28APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704003 | Standard of Care | INFECTIONS AND INFESTATIONS | CERVICITIS | 11MAY2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704004 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 06JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704004 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 06AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 25AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 26OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704004 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | GASTROINTESTINAL HAEMORRHAGE | 27JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 09FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704004 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 11APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704005 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 20JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 21AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704009 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 02FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704009 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 04MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704009 | Clinwrightinib 200 mg | REPRODUCTIVE SYSTEM AND BREAST DISORDERS | BENIGN PROSTATIC HYPERPLASIA | 24APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704009 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 22MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704011 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 24AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704011 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | SALIVARY HYPERSECRETION | 30AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704011 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 01JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704011 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | PAROSMIA | 24FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704011 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 03JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704011 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 24JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704012 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 14AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704012 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 18AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704012 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 09SEP2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704013 | Standard of Care | GASTROINTESTINAL DISORDERS | ABDOMINAL PAIN | 10SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704013 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 24SEP2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704013 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN ULCER | 27SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704013 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE REACTION | 07OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704013 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 18OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704013 | Standard of Care | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 05MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704014 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 19JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704014 | Standard of Care | CARDIAC DISORDERS | BRADYCARDIA | 16APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704014 | Standard of Care | NERVOUS SYSTEM DISORDERS | DIZZINESS | 23JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704015 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 08DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704015 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 11JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 14MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704016 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FIBRILLATION | 25JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704016 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 08MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704016 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | DIARRHOEA | 26MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704016 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 06JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704017 | Standard of Care | GASTROINTESTINAL DISORDERS | DYSPEPSIA | 26DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704017 | Standard of Care | INFECTIONS AND INFESTATIONS | BRONCHITIS | 17JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704017 | Standard of Care | SURGICAL AND MEDICAL PROCEDURES | EYE LASER SURGERY | 25JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704019 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 16JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704019 | Standard of Care | NERVOUS SYSTEM DISORDERS | PARKINSON'S DISEASE | 24JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704019 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 26JAN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704020 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 04MAR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704020 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 14JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704020 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 01SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704021 | Standard of Care | INFECTIONS AND INFESTATIONS | EAR INFECTION | 19JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704021 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 14AUG2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704021 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 26OCT2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704022 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 23FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704022 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 07JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704022 | Clinwrightinib 200 mg | INVESTIGATIONS | BIOPSY | 09JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704022 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 10JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704022 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23OCT2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704022 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 08NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704022 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PERSPIRATION | 13DEC2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704023 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | HIP FRACTURE | 13APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704023 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 03SEP2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704026 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 19APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704026 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 21MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704026 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 09JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704026 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | INSOMNIA | 19JUN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704026 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH PRURITIC | 28OCT2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704026 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 06DEC2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704026 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 25DEC2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704027 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHILLS | 04APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704027 | Standard of Care | NERVOUS SYSTEM DISORDERS | DIZZINESS | 05APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704027 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704027 | Standard of Care | GASTROINTESTINAL DISORDERS | NAUSEA | 29APR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704027 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 21MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704028 | Standard of Care | GASTROINTESTINAL DISORDERS | DYSPEPSIA | 17JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704028 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 09FEB2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704028 | Standard of Care | INFECTIONS AND INFESTATIONS | PNEUMONIA | 16FEB2024 | SEVERE | Y | FATAL |
| ONCO-EX-704028 | Standard of Care | CARDIAC DISORDERS | ATRIAL HYPERTROPHY | 28FEB2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704029 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 08JUN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704029 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 29AUG2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-704030 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 28APR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704030 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 18MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704030 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 27JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704030 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 05JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704030 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 29SEP2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704031 | Clinwrightinib 200 mg | VASCULAR DISORDERS | HYPERTENSION | 20JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704031 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SUPRAVENTRICULAR EXTRASYSTOLES | 27JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704031 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | SALIVARY HYPERSECRETION | 14SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704032 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 16JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704033 | Standard of Care | EYE DISORDERS | EYE ALLERGY | 06SEP2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-704033 | Standard of Care | INVESTIGATIONS | HEART RATE IRREGULAR | 20DEC2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704033 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 07MAR2024 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-704034 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | BACK PAIN | 19JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704034 | Clinwrightinib 200 mg | METABOLISM AND NUTRITION DISORDERS | DECREASED APPETITE | 20JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704034 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 29JAN2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704035 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 12JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704035 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 31JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704035 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH PRURITIC | 26AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704035 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 07OCT2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704035 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 21NOV2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-704035 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 05DEC2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-704035 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | INFLUENZA | 06DEC2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705001 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 26JAN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705001 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | ASTHENIA | 02MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705002 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 16FEB2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705002 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 04MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705002 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 06MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705002 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 10MAR2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705002 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 20MAR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705002 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 25MAR2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705002 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 31MAR2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705003 | Standard of Care | RENAL AND URINARY DISORDERS | POLLAKIURIA | 18FEB2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705003 | Standard of Care | CARDIAC DISORDERS | BRADYCARDIA | 01MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705003 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 10MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705003 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 14MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705003 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 22MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705004 | Clinwrightinib 200 mg | INVESTIGATIONS | ELECTROCARDIOGRAM T WAVE INVERSION | 09MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705004 | Clinwrightinib 200 mg | METABOLISM AND NUTRITION DISORDERS | DECREASED APPETITE | 04JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705004 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 15DEC2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 19DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705004 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | INFLUENZA | 21DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHEST DISCOMFORT | 02JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FEELING COLD | 01FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705005 | Standard of Care | EYE DISORDERS | GLAUCOMA | 12SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705005 | Standard of Care | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 06OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705005 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 22NOV2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-705005 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 11DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705005 | Standard of Care | INVESTIGATIONS | HEART RATE IRREGULAR | 13DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705005 | Standard of Care | HEPATOBILIARY DISORDERS | HYPERBILIRUBINAEMIA | 06MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705006 | Standard of Care | EAR AND LABYRINTH DISORDERS | EAR PAIN | 14AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705006 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | COLD SWEAT | 09NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705007 | Standard of Care | INVESTIGATIONS | ELECTROCARDIOGRAM ST SEGMENT DEPRESSION | 03AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705008 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 08JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705008 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 05JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705008 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 24FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 19MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705011 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN ULCER | 20JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705012 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | HALLUCINATION, VISUAL | 01JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705012 | Clinwrightinib 200 mg | EYE DISORDERS | VISION BLURRED | 06JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705012 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PERSPIRATION | 09JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705012 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 15JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705012 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 09AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705012 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 11AUG2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705013 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | PHARYNGEAL ERYTHEMA | 23AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705013 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 17SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705013 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | HIP FRACTURE | 17OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705013 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | SALIVARY HYPERSECRETION | 26OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705013 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 31DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705013 | Clinwrightinib 200 mg | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 27JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705015 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 06APR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 01JUL2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-705015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 08JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705015 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | DIARRHOEA | 26JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705016 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 17OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705016 | Standard of Care | CARDIAC DISORDERS | TACHYCARDIA | 31OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705016 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | COLD SWEAT | 01NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705016 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE REACTION | 29NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705017 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | FACIAL BONES FRACTURE | 08NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705017 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 18FEB2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705017 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | SYNCOPE | 01AUG2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705017 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 26SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705017 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | BLISTER | 01OCT2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705018 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FIBRILLATION | 09NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705018 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | DEPRESSED MOOD | 22NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705018 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 04DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705019 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HYPERSOMNIA | 26FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705019 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | PAROSMIA | 01MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705019 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 21MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705020 | Standard of Care | EAR AND LABYRINTH DISORDERS | EAR PAIN | 23DEC2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-705020 | Standard of Care | INFECTIONS AND INFESTATIONS | EAR INFECTION | 16APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705020 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 16APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705021 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FIBRILLATION | 28FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705021 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | SALIVARY HYPERSECRETION | 02APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705021 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 03APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705021 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | PAROSMIA | 08NOV2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705022 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 01FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705022 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 06FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705022 | Standard of Care | VASCULAR DISORDERS | ORTHOSTATIC HYPOTENSION | 09JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705023 | Standard of Care | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK FIRST DEGREE | 23OCT2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705024 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 29JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705024 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 06FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705025 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 15JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705025 | Clinwrightinib 200 mg | EAR AND LABYRINTH DISORDERS | VERTIGO | 03JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705025 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | INSOMNIA | 19SEP2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-705025 | Clinwrightinib 200 mg | INVESTIGATIONS | BLOOD GLUCOSE INCREASED | 21OCT2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705025 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 27OCT2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-705026 | Standard of Care | INVESTIGATIONS | BLOOD URINE PRESENT | 09DEC2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-705026 | Standard of Care | EYE DISORDERS | GLAUCOMA | 04JAN2024 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-706001 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-706001 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 31AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-706001 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | PYREXIA | 14OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-706003 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 16JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-706003 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | LOWER RESPIRATORY TRACT INFECTION | 22JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-706003 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 26JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-706003 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 06FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-707001 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 21SEP2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-707001 | Standard of Care | VASCULAR DISORDERS | ORTHOSTATIC HYPOTENSION | 28OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-707001 | Standard of Care | INFECTIONS AND INFESTATIONS | GASTROENTERITIS VIRAL | 24NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-707001 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | FOOD CRAVING | 13DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708001 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 29JAN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708001 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 31JAN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708001 | Standard of Care | EYE DISORDERS | CONJUNCTIVITIS | 01FEB2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708001 | Standard of Care | INVESTIGATIONS | BLOOD URINE PRESENT | 03FEB2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708001 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 01MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708001 | Standard of Care | INFECTIONS AND INFESTATIONS | EAR INFECTION | 06MAR2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708003 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 28DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708003 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 02FEB2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708004 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 11JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 26NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708004 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | SALIVARY HYPERSECRETION | 27NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708004 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 03FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708004 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 17FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708004 | Clinwrightinib 200 mg | VASCULAR DISORDERS | WOUND HAEMORRHAGE | 05MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708005 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 07JUN2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708005 | Standard of Care | INVESTIGATIONS | HEART RATE IRREGULAR | 10JUN2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708005 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 18JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708007 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 12JUL2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-708007 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 14AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708007 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 29OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708007 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 13NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708007 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 08JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708007 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | RHINITIS | 12JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708008 | Standard of Care | INVESTIGATIONS | HEART RATE INCREASED | 30SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708009 | Standard of Care | GASTROINTESTINAL DISORDERS | NAUSEA | 31JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708009 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 04AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708009 | Standard of Care | INVESTIGATIONS | CYSTOSCOPY | 03SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708009 | Standard of Care | PSYCHIATRIC DISORDERS | IRRITABILITY | 03SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708010 | Standard of Care | GASTROINTESTINAL DISORDERS | FLATULENCE | 03SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708010 | Standard of Care | CARDIAC DISORDERS | CARDIAC FAILURE CONGESTIVE | 05OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708011 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | BLISTER | 20OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708011 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 01MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708011 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 12JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708012 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 31AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708012 | Standard of Care | PSYCHIATRIC DISORDERS | AGITATION | 09SEP2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-708012 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 15SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708012 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 11OCT2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708013 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708013 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 09NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708013 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 04JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708013 | Standard of Care | INFECTIONS AND INFESTATIONS | URINARY TRACT INFECTION | 24FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708015 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 28OCT2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708015 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | PNEUMONIA | 26NOV2022 | SEVERE | Y | FATAL |
| ONCO-EX-708015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 30NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 30NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708015 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | EPISTAXIS | 01DEC2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708016 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | ABDOMINAL PAIN | 08JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708016 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 25MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708016 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 16SEP2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708016 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 18SEP2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708017 | Standard of Care | INFECTIONS AND INFESTATIONS | URINARY TRACT INFECTION | 16DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708017 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 19JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708017 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | DECREASED APPETITE | 31AUG2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708018 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 31OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708018 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 05FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708018 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 06FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708018 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | MALAISE | 03MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708018 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 05MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708018 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 28JUN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708018 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 09AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708018 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 07SEP2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708021 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 17FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708021 | Standard of Care | CARDIAC DISORDERS | TACHYCARDIA | 28APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708023 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | STOMACH DISCOMFORT | 23JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708023 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 08FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708023 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | SOMNOLENCE | 13FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708023 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 26FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708023 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 25APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708023 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 30APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708023 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 05MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708023 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | BACK PAIN | 22AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708023 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHEST PAIN | 24SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708024 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 25MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708024 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | BACK PAIN | 11MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708024 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | HIP FRACTURE | 27MAY2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-708024 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 27JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708024 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 29JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708024 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 02JUL2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708024 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 13JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708025 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | PAIN IN EXTREMITY | 18FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708027 | Clinwrightinib 200 mg | RENAL AND URINARY DISORDERS | NEPHROLITHIASIS | 12FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708027 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | RESPIRATORY TRACT CONGESTION | 09MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708027 | Clinwrightinib 200 mg | IMMUNE SYSTEM DISORDERS | SEASONAL ALLERGY | 07APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708027 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 13MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708027 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 25JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708027 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 18JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708028 | Standard of Care | EYE DISORDERS | EYE SWELLING | 10MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708028 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 10MAR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708028 | Standard of Care | RENAL AND URINARY DISORDERS | POLLAKIURIA | 27MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708029 | Standard of Care | NERVOUS SYSTEM DISORDERS | PARKINSON'S DISEASE | 13MAR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708029 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 18MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708029 | Standard of Care | INVESTIGATIONS | ELECTROCARDIOGRAM T WAVE INVERSION | 18MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708029 | Standard of Care | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 26MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708029 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | PAIN IN EXTREMITY | 05APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708029 | Standard of Care | NERVOUS SYSTEM DISORDERS | SOMNOLENCE | 11APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708029 | Standard of Care | INVESTIGATIONS | ELECTROCARDIOGRAM ST SEGMENT DEPRESSION | 19APR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708029 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 20APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708030 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | RALES | 17JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708030 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 23AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708030 | Standard of Care | REPRODUCTIVE SYSTEM AND BREAST DISORDERS | PELVIC PAIN | 08FEB2024 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708031 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 30SEP2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-708031 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 02NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708031 | Clinwrightinib 200 mg | EYE DISORDERS | VISION BLURRED | 14JAN2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708031 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 04FEB2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708033 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 05SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-708034 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 11JUL2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708034 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH MACULO-PAPULAR | 16OCT2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-708034 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 18DEC2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | ASTHENIA | 08APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 12MAY2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709001 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 20MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709001 | Clinwrightinib 200 mg | INVESTIGATIONS | BLOOD CHOLESTEROL INCREASED | 05JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709001 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23JUL2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709001 | Clinwrightinib 200 mg | RENAL AND URINARY DISORDERS | NEPHROLITHIASIS | 05AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709002 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 19AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709002 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | BURNING SENSATION | 22NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709002 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709003 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 20MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709003 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 21MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709003 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 09APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709003 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 09APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709003 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | DERMATITIS ATOPIC | 27APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709004 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 25APR2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709004 | Standard of Care | INFECTIONS AND INFESTATIONS | CERVICITIS | 28APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709005 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE REACTION | 17MAR2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709005 | Standard of Care | GASTROINTESTINAL DISORDERS | NAUSEA | 03APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709005 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 26APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709006 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | HIP FRACTURE | 28JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709006 | Standard of Care | PSYCHIATRIC DISORDERS | CONFUSIONAL STATE | 23AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709006 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 30AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709007 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | FALL | 01AUG2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709007 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE URTICARIA | 19SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709007 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 08OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709007 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | LIBIDO DECREASED | 30NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709007 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 09MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709008 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 30APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709008 | Standard of Care | INVESTIGATIONS | BLOOD URINE PRESENT | 03MAY2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709008 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 04JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709009 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 30JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709009 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 01SEP2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709009 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | HALLUCINATION, VISUAL | 28SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 04NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709010 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 20JUN2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709010 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | BACK PAIN | 06JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709011 | Standard of Care | GASTROINTESTINAL DISORDERS | NAUSEA | 29JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709011 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 01AUG2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709011 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | POSTNASAL DRIP | 29DEC2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709014 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 01DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709015 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 29DEC2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709015 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | HIP FRACTURE | 04JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709016 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 22FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709016 | Clinwrightinib 200 mg | CONGENITAL, FAMILIAL AND GENETIC DISORDERS | VENTRICULAR SEPTAL DEFECT | 27MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709016 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 29JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709016 | Clinwrightinib 200 mg | CARDIAC DISORDERS | VENTRICULAR EXTRASYSTOLES | 02AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709018 | Clinwrightinib 200 mg | CONGENITAL, FAMILIAL AND GENETIC DISORDERS | VENTRICULAR SEPTAL DEFECT | 19JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709018 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 10OCT2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709018 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | DYSPEPSIA | 01NOV2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709019 | Standard of Care | REPRODUCTIVE SYSTEM AND BREAST DISORDERS | BENIGN PROSTATIC HYPERPLASIA | 18JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709019 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 24JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709019 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 26JAN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709019 | Standard of Care | VASCULAR DISORDERS | HYPOTENSION | 27JAN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709019 | Standard of Care | INVESTIGATIONS | ELECTROCARDIOGRAM ST SEGMENT DEPRESSION | 09FEB2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-709019 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 09FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709019 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 20FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709019 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 23SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709021 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 01FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709021 | Standard of Care | EYE DISORDERS | CONJUNCTIVITIS | 07FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709021 | Standard of Care | INVESTIGATIONS | HEART RATE INCREASED | 18FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709021 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 20FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709021 | Standard of Care | PSYCHIATRIC DISORDERS | ANXIETY | 24FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709021 | Standard of Care | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 13MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709021 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 15MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709022 | Standard of Care | GASTROINTESTINAL DISORDERS | DYSPEPSIA | 05FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709022 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | DEHYDRATION | 12FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709022 | Standard of Care | INVESTIGATIONS | HEART RATE IRREGULAR | 13FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709022 | Standard of Care | GASTROINTESTINAL DISORDERS | ABDOMINAL PAIN | 23FEB2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709022 | Standard of Care | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 25FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709022 | Standard of Care | CARDIAC DISORDERS | BUNDLE BRANCH BLOCK LEFT | 18MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709023 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 27AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709023 | Standard of Care | CARDIAC DISORDERS | SINUS BRADYCARDIA | 18SEP2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709024 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 11JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709024 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FIBRILLATION | 17JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709024 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 01NOV2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709025 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 27MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709025 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 01AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709025 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 28AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709025 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 15OCT2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709025 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 12NOV2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709027 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 22MAR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709027 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 21APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709027 | Clinwrightinib 200 mg | EYE DISORDERS | VISION BLURRED | 16MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709027 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FLUTTER | 19JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709027 | Clinwrightinib 200 mg | METABOLISM AND NUTRITION DISORDERS | DECREASED APPETITE | 28AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709027 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 30AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709027 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PERSPIRATION | 11SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709027 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 24NOV2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709028 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 05JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709028 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 26JAN2024 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709029 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 28APR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709029 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 13MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709029 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 04JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709029 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 07JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-709030 | Standard of Care | INFECTIONS AND INFESTATIONS | INFLUENZA | 30MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709030 | Standard of Care | NERVOUS SYSTEM DISORDERS | SOMNOLENCE | 15JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709030 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | DEHYDRATION | 26JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709032 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 24JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709032 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 31JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-709032 | Clinwrightinib 200 mg | INVESTIGATIONS | BLOOD CHOLESTEROL INCREASED | 30AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-709032 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | ABDOMINAL DISCOMFORT | 31AUG2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710001 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 25DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710002 | Standard of Care | INVESTIGATIONS | ELECTROCARDIOGRAM ST SEGMENT DEPRESSION | 26AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710003 | Clinwrightinib 200 mg | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 25FEB2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710003 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 26MAY2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710003 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 30AUG2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-710003 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PERSPIRATION | 20OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710003 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | SALIVARY HYPERSECRETION | 29NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710004 | Standard of Care | RENAL AND URINARY DISORDERS | POLLAKIURIA | 02MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710004 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 16MAR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710004 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 02DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710005 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 10MAR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710005 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 22MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710005 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 11MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710005 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | PRODUCTIVE COUGH | 29MAY2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710006 | Clinwrightinib 200 mg | INVESTIGATIONS | BLOOD GLUCOSE INCREASED | 22APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710006 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 04MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710006 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 19JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710006 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 01AUG2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-710006 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FLUTTER | 16SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710006 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 31DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710007 | Standard of Care | CARDIAC DISORDERS | ATRIAL HYPERTROPHY | 02DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710008 | Standard of Care | REPRODUCTIVE SYSTEM AND BREAST DISORDERS | BENIGN PROSTATIC HYPERPLASIA | 24MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710008 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | COLD SWEAT | 06APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710008 | Standard of Care | INVESTIGATIONS | ELECTROCARDIOGRAM T WAVE INVERSION | 14APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710008 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 18APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710009 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | POSTNASAL DRIP | 24MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710009 | Standard of Care | INVESTIGATIONS | HEART RATE INCREASED | 05APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710009 | Standard of Care | VASCULAR DISORDERS | HYPERTENSION | 13APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710009 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 16APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710011 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 21JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710011 | Standard of Care | PSYCHIATRIC DISORDERS | COMPLETED SUICIDE | 26JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710011 | Standard of Care | VASCULAR DISORDERS | HYPERTENSION | 22AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710011 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 11JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710011 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 18FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710012 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 22APR2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710012 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHILLS | 25APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710012 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 25APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710012 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 16MAY2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710013 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 19JUL2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710013 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 20AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710013 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 06SEP2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710015 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 25MAY2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710015 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 31MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710015 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 05JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 15JUN2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-710015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 22JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710015 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 26JUN2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710015 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 03JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710015 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | SYNCOPE VASOVAGAL | 06JUL2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710016 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 05JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710016 | Standard of Care | INFECTIONS AND INFESTATIONS | CERVICITIS | 10JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710016 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | DIABETES MELLITUS | 11JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710016 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | EMPHYSEMA | 16JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710016 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 29JUN2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710017 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 01JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710017 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 23JUL2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-710017 | Standard of Care | INFECTIONS AND INFESTATIONS | URINARY TRACT INFECTION | 15AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710017 | Standard of Care | PSYCHIATRIC DISORDERS | IRRITABILITY | 26AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710017 | Standard of Care | VASCULAR DISORDERS | HYPOTENSION | 13OCT2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710017 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 26OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710018 | Standard of Care | INFECTIONS AND INFESTATIONS | CERVICITIS | 28JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710018 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN ULCER | 05JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710018 | Standard of Care | PSYCHIATRIC DISORDERS | INSOMNIA | 28JUL2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710019 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 31OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710019 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FLUTTER | 19NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710019 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PERSPIRATION | 01DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710019 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 07JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710020 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH MACULO-PAPULAR | 09JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710021 | Standard of Care | INFECTIONS AND INFESTATIONS | EAR INFECTION | 28NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710021 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 15FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710021 | Standard of Care | NERVOUS SYSTEM DISORDERS | PARKINSON'S DISEASE | 05APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710021 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 11MAY2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710022 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 24SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710022 | Clinwrightinib 200 mg | SURGICAL AND MEDICAL PROCEDURES | SKIN LESION EXCISION | 18OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710022 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH PAPULAR | 13FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710022 | Clinwrightinib 200 mg | VASCULAR DISORDERS | HYPERTENSION | 11MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710022 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | DIARRHOEA | 09MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710022 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 10MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710024 | Standard of Care | GASTROINTESTINAL DISORDERS | NAUSEA | 27MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710025 | Standard of Care | HEPATOBILIARY DISORDERS | HYPERBILIRUBINAEMIA | 11AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710025 | Standard of Care | CARDIAC DISORDERS | SINUS BRADYCARDIA | 03SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710025 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | POSTNASAL DRIP | 19SEP2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-710025 | Standard of Care | NERVOUS SYSTEM DISORDERS | DIZZINESS | 23SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710026 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 07NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710026 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 26MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710026 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 25JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710028 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 16OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710028 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 24OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710028 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 28JAN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710028 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 28APR2023 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710030 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 16DEC2022 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710030 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | AMNESIA | 01JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710030 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FEELING COLD | 27MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710030 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 07AUG2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710031 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 21NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710031 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 28NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710031 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 04DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710032 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 10FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710032 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 17MAY2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710036 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | URINARY TRACT INFECTION | 01APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710036 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 17JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710036 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 02JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710036 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 23SEP2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710037 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE SWELLING | 25JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710037 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 02MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710037 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FIBRILLATION | 07MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710037 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 26MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710037 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 31MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710037 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | RHINORRHOEA | 03APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710037 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 15APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710038 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH MACULO-PAPULAR | 03FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710038 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 28FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710038 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | AMNESIA | 25APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710038 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 01MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710038 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | GASTROINTESTINAL HAEMORRHAGE | 28MAY2023 | SEVERE | Y | FATAL |
| ONCO-EX-710041 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 12MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710041 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 06APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710042 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 11APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710042 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 03AUG2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710042 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 06AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710042 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 24AUG2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710042 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 28NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710042 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | ABDOMINAL PAIN | 02DEC2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710042 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 08DEC2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710042 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH PRURITIC | 24JAN2024 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710043 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 14MAY2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710043 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 29SEP2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710043 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | ABDOMINAL DISCOMFORT | 08NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710043 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 15DEC2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710043 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 02FEB2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710044 | Standard of Care | CARDIAC DISORDERS | ATRIAL HYPERTROPHY | 02APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710044 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 15MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710044 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 20MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710045 | Standard of Care | PSYCHIATRIC DISORDERS | ANXIETY | 28MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710045 | Standard of Care | EYE DISORDERS | EYE ALLERGY | 09APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710046 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 17JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710046 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 01NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710046 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 16DEC2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710046 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 08JAN2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710048 | Clinwrightinib 200 mg | CONGENITAL, FAMILIAL AND GENETIC DISORDERS | VENTRICULAR SEPTAL DEFECT | 17MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710048 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 18MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710048 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | LOWER RESPIRATORY TRACT INFECTION | 22AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710048 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 26NOV2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710048 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 19JAN2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710048 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 06FEB2024 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710048 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHEST DISCOMFORT | 13FEB2024 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-710049 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 04JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710049 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ACTINIC KERATOSIS | 26NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710049 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | RESPIRATORY TRACT CONGESTION | 14FEB2024 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710049 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 22FEB2024 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710049 | Clinwrightinib 200 mg | RENAL AND URINARY DISORDERS | CALCULUS URETHRAL | 17MAR2024 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710050 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHILLS | 28MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710050 | Standard of Care | CARDIAC DISORDERS | SUPRAVENTRICULAR EXTRASYSTOLES | 12JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710050 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | RALES | 04JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710050 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | SKIN LACERATION | 05JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710052 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | PAROSMIA | 18SEP2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710052 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 27SEP2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-710052 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 25OCT2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710052 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | STOMACH DISCOMFORT | 31JAN2025 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710053 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 30JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710053 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIAL FLUTTER | 04JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710053 | Clinwrightinib 200 mg | EYE DISORDERS | VISION BLURRED | 06JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710053 | Clinwrightinib 200 mg | INVESTIGATIONS | WEIGHT DECREASED | 08JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-710053 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 11JUL2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710053 | Clinwrightinib 200 mg | RENAL AND URINARY DISORDERS | NEPHROLITHIASIS | 13JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710054 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 16SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-710054 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | BACK PAIN | 22SEP2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-710054 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 08APR2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-711001 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | BURNING SENSATION | 31MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-711001 | Clinwrightinib 200 mg | PSYCHIATRIC DISORDERS | HALLUCINATION | 28JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-711001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 06NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-711002 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 03JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-711002 | Standard of Care | EYE DISORDERS | CONJUNCTIVITIS | 19JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-711003 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 25FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-711004 | Standard of Care | PSYCHIATRIC DISORDERS | CONFUSIONAL STATE | 21NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-711004 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 05FEB2023 | MILD | Y | RECOVERED/RESOLVED |
| ONCO-EX-711004 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 05APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-713002 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 03JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-713002 | Clinwrightinib 200 mg | REPRODUCTIVE SYSTEM AND BREAST DISORDERS | BENIGN PROSTATIC HYPERPLASIA | 11JAN2024 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-713003 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 27JUL2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-713003 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 11AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-713003 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | BACK PAIN | 08DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-713004 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 02NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-713004 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 16NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-713005 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 02DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-713006 | Clinwrightinib 200 mg | CARDIAC DISORDERS | CARDIAC DISORDER | 12DEC2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-713006 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH PRURITIC | 28DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-713006 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE URTICARIA | 11MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-713006 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | FLANK PAIN | 10AUG2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-713007 | Standard of Care | CARDIAC DISORDERS | BUNDLE BRANCH BLOCK RIGHT | 18FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-713007 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE REACTION | 06APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-713007 | Standard of Care | INVESTIGATIONS | BLOOD CREATINE PHOSPHOKINASE INCREASED | 06APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-713007 | Standard of Care | VASCULAR DISORDERS | HYPERTENSION | 06APR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-713007 | Standard of Care | HEPATOBILIARY DISORDERS | HYPERBILIRUBINAEMIA | 09JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 06APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714001 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 09APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714001 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 10APR2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714001 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | AMNESIA | 11APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 13APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 27APR2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714001 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 03MAY2022 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714002 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 11JUN2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714002 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE REACTION | 12JUN2022 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714002 | Standard of Care | CARDIAC DISORDERS | ATRIAL HYPERTROPHY | 01JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714004 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 16JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714005 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 08JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714005 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | SHOULDER PAIN | 09JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714005 | Standard of Care | INFECTIONS AND INFESTATIONS | EAR INFECTION | 15JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714005 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23JUL2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714005 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 15AUG2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714005 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE INDURATION | 17AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714005 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 22AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714006 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 09SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714006 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 15SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714006 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 19OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714006 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 24OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714006 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 27MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 08FEB2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PAIN | 21JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714008 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 22JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714008 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS GENERALISED | 06AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 05SEP2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 08SEP2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-714008 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 15NOV2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714010 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | EXCORIATION | 25MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714010 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 15AUG2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714010 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 08SEP2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-714010 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 16SEP2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-714010 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ALOPECIA | 01MAR2024 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715001 | Clinwrightinib 200 mg | VASCULAR DISORDERS | HYPERTENSION | 09FEB2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715001 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 13MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715001 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 12APR2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715001 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 21SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715001 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 21SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715001 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | LETHARGY | 25DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715002 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | NASOPHARYNGITIS | 25JAN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715002 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 21APR2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715002 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 27APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715002 | Clinwrightinib 200 mg | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 06JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715002 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 23SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715002 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 15JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715003 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE URTICARIA | 16MAY2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715003 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 07AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715003 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 09OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715003 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 27FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715004 | Standard of Care | INVESTIGATIONS | HEART RATE INCREASED | 14MAY2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715004 | Standard of Care | GASTROINTESTINAL DISORDERS | NAUSEA | 25MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715004 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 26MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715004 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | DECREASED APPETITE | 13JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715008 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 12DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715008 | Clinwrightinib 200 mg | EYE DISORDERS | VISION BLURRED | 04JAN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 13JAN2023 | MILD | Y | RECOVERED/RESOLVED |
| ONCO-EX-715008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 17FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715008 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 05MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715008 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | ABDOMINAL DISCOMFORT | 03APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE REACTION | 11APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715009 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 22NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715009 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 04DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715010 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 12MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 01MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715010 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 04JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715010 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 04JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715010 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | ARTHRITIS | 06JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PERSPIRATION | 14JUN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 07AUG2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-715013 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 01AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-715013 | Standard of Care | REPRODUCTIVE SYSTEM AND BREAST DISORDERS | PELVIC PAIN | 02AUG2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715013 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 24DEC2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715013 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 13JAN2024 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715013 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 04FEB2024 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-715013 | Standard of Care | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 29APR2024 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716001 | Standard of Care | CARDIAC DISORDERS | ATRIAL HYPERTROPHY | 30JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716004 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 03APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716004 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 30APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716004 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | SKIN LACERATION | 02OCT2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716004 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 15OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716004 | Standard of Care | EYE DISORDERS | CONJUNCTIVITIS | 24OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716004 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | POSTNASAL DRIP | 27OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 29MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716009 | Clinwrightinib 200 mg | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 19JUL2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 23JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716009 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 27SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716009 | Clinwrightinib 200 mg | INVESTIGATIONS | ELECTROCARDIOGRAM T WAVE INVERSION | 17JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716009 | Clinwrightinib 200 mg | INVESTIGATIONS | WEIGHT DECREASED | 16FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 16JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716010 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 30JUN2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716010 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 26SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716010 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | BLISTER | 27SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716010 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 26DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 08JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 22APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 02MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE REACTION | 11OCT2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716011 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | COLD SWEAT | 26JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716011 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 27JUN2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716011 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | DIABETES MELLITUS | 19JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716011 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 19JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716011 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 07AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716012 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 06AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716012 | Standard of Care | GASTROINTESTINAL DISORDERS | DYSPEPSIA | 14AUG2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716012 | Standard of Care | EYE DISORDERS | EYE SWELLING | 17AUG2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716013 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 17AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716013 | Clinwrightinib 200 mg | SURGICAL AND MEDICAL PROCEDURES | SKIN LESION EXCISION | 29AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716013 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 19SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716013 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE VESICLES | 04NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716013 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 05NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716013 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | HEADACHE | 19NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716013 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | PRODUCTIVE COUGH | 26JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716013 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 27JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716013 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 07JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE SWELLING | 21SEP2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716015 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | LOWER RESPIRATORY TRACT INFECTION | 19NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716015 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | RHINITIS | 28NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716015 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 11DEC2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716015 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 05MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716015 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 05MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716016 | Standard of Care | INFECTIONS AND INFESTATIONS | INFLUENZA | 11FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716016 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 03MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716016 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 18JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716018 | Standard of Care | GASTROINTESTINAL DISORDERS | FLATULENCE | 24SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716018 | Standard of Care | INVESTIGATIONS | ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED | 29NOV2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716018 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 01DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716018 | Standard of Care | CARDIAC DISORDERS | BRADYCARDIA | 26DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716019 | Standard of Care | VASCULAR DISORDERS | HYPERTENSION | 30OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716019 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE INDURATION | 15NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716019 | Standard of Care | CARDIAC DISORDERS | ATRIAL HYPERTROPHY | 12DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716020 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 22DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716020 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 09JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716020 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 23JAN2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716020 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 01JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716020 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 07JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716020 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 14AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716020 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 25AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716021 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 14NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716021 | Standard of Care | INFECTIONS AND INFESTATIONS | BRONCHITIS | 25NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716023 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | DERMATITIS ATOPIC | 31MAR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716023 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 25MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716023 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 10JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716023 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 20JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716023 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 30JUL2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716025 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 18FEB2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716025 | Standard of Care | INFECTIONS AND INFESTATIONS | VAGINAL MYCOSIS | 23FEB2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716026 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | PARTIAL SEIZURES WITH SECONDARY GENERALISATION | 18MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716026 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 15JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716027 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE SWELLING | 11FEB2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716027 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | LOWER RESPIRATORY TRACT INFECTION | 28FEB2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716027 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | MALAISE | 25SEP2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716027 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | SYNCOPE | 13NOV2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716028 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 12MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716028 | Standard of Care | INVESTIGATIONS | BLOOD ALKALINE PHOSPHATASE INCREASED | 02JUN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716028 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 12JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716031 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 02MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716031 | Standard of Care | CARDIAC DISORDERS | BUNDLE BRANCH BLOCK LEFT | 07MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716031 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 09MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716031 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | EMPHYSEMA | 11MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716031 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 12MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716031 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 20MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716031 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 23MAR2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716031 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 13MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716032 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | CHEST DISCOMFORT | 19AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716032 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 22OCT2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716032 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PAIN | 17NOV2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716034 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 23MAY2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-716034 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | SYNCOPE VASOVAGAL | 25MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716034 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | PAROSMIA | 26MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716034 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH PAPULAR | 09JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716035 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 10MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716035 | Standard of Care | INFECTIONS AND INFESTATIONS | GASTROENTERITIS VIRAL | 14MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716035 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | SHOULDER PAIN | 25OCT2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716036 | Standard of Care | EAR AND LABYRINTH DISORDERS | EAR PAIN | 09MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716036 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 21NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716036 | Standard of Care | EYE DISORDERS | EYE PRURITUS | 17DEC2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716036 | Standard of Care | GASTROINTESTINAL DISORDERS | ABDOMINAL PAIN | 22DEC2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716036 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 21JAN2024 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716037 | Standard of Care | INVESTIGATIONS | CYSTOSCOPY | 28APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716037 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | SKIN IRRITATION | 01MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716037 | Standard of Care | GASTROINTESTINAL DISORDERS | VOMITING | 07MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716037 | Standard of Care | INFECTIONS AND INFESTATIONS | EAR INFECTION | 16MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-716037 | Standard of Care | INFECTIONS AND INFESTATIONS | LOCALISED INFECTION | 16MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716037 | Standard of Care | VASCULAR DISORDERS | HYPOTENSION | 17MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716037 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 05JUN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-716037 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 11JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716038 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | HYPERHIDROSIS | 11JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-716038 | Standard of Care | CARDIAC DISORDERS | VENTRICULAR HYPERTROPHY | 07AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717001 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 26MAR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717001 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 16APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717001 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 21APR2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717001 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 29APR2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717001 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | LOWER RESPIRATORY TRACT INFECTION | 04MAY2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717003 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE REACTION | 28SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717003 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 29SEP2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717003 | Standard of Care | INFECTIONS AND INFESTATIONS | INFLUENZA | 16JAN2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717003 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 04APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717005 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | EXCORIATION | 19AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717005 | Standard of Care | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | HIP FRACTURE | 28AUG2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717005 | Standard of Care | INFECTIONS AND INFESTATIONS | BRONCHITIS | 14SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717005 | Standard of Care | INFECTIONS AND INFESTATIONS | UPPER RESPIRATORY TRACT INFECTION | 19SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717005 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | NASAL CONGESTION | 25SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717006 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 04SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717006 | Standard of Care | GASTROINTESTINAL DISORDERS | HIATUS HERNIA | 13SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717006 | Standard of Care | CARDIAC DISORDERS | SUPRAVENTRICULAR EXTRASYSTOLES | 15SEP2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717006 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 16SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717006 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | ARTHRITIS | 16SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717006 | Standard of Care | PSYCHIATRIC DISORDERS | CONFUSIONAL STATE | 17OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717006 | Standard of Care | NERVOUS SYSTEM DISORDERS | SOMNOLENCE | 17OCT2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-717007 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 22DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717007 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE IRRITATION | 05MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717007 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 30MAY2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717008 | Standard of Care | INFECTIONS AND INFESTATIONS | LOCALISED INFECTION | 23APR2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717009 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 14MAR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717009 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | DIZZINESS | 29MAR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717009 | Clinwrightinib 200 mg | VASCULAR DISORDERS | WOUND HAEMORRHAGE | 11APR2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 09JUN2023 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717009 | Clinwrightinib 200 mg | NERVOUS SYSTEM DISORDERS | PARTIAL SEIZURES WITH SECONDARY GENERALISATION | 24JUL2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-717009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 21AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 28AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717010 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 27MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 12AUG2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 16SEP2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717010 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | FATIGUE | 02NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717011 | Standard of Care | EYE DISORDERS | CONJUNCTIVITIS | 07MAY2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-717011 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | INCREASED APPETITE | 30JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717012 | Standard of Care | CARDIAC DISORDERS | VENTRICULAR HYPERTROPHY | 23MAR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717012 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | COLD SWEAT | 21APR2023 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-717012 | Standard of Care | INVESTIGATIONS | HEART RATE IRREGULAR | 24APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717012 | Standard of Care | METABOLISM AND NUTRITION DISORDERS | FOOD CRAVING | 09MAY2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-717012 | Standard of Care | EAR AND LABYRINTH DISORDERS | EAR PAIN | 24APR2024 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718001 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 06JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718001 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | SHOULDER PAIN | 08SEP2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718002 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 27NOV2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718003 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | ASTHENIA | 14MAY2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718003 | Standard of Care | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK FIRST DEGREE | 05JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718004 | Standard of Care | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | RASH | 07JUL2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-718004 | Standard of Care | NERVOUS SYSTEM DISORDERS | HEADACHE | 04DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718004 | Standard of Care | CARDIAC DISORDERS | MYOCARDIAL INFARCTION | 31DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-718004 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 01JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718005 | Standard of Care | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE DERMATITIS | 01JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718005 | Standard of Care | GASTROINTESTINAL DISORDERS | DIARRHOEA | 01JUN2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718005 | Standard of Care | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | POSTNASAL DRIP | 06JUL2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718005 | Standard of Care | INVESTIGATIONS | BLOOD CREATINE PHOSPHOKINASE INCREASED | 06OCT2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-718005 | Standard of Care | REPRODUCTIVE SYSTEM AND BREAST DISORDERS | BENIGN PROSTATIC HYPERPLASIA | 01DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718006 | Clinwrightinib 200 mg | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | CONTUSION | 11JUN2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718006 | Clinwrightinib 200 mg | CONGENITAL, FAMILIAL AND GENETIC DISORDERS | VENTRICULAR SEPTAL DEFECT | 12JUN2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-718006 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | ERYTHEMA | 16JUN2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718006 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS GENERALISED | 29JUN2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718006 | Clinwrightinib 200 mg | SURGICAL AND MEDICAL PROCEDURES | SKIN LESION EXCISION | 01JUL2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718008 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 03SEP2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PRURITUS | 15OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718008 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | BACK PAIN | 01NOV2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-718008 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 01DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-718008 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | PRODUCTIVE COUGH | 17DEC2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-718008 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | STOMACH DISCOMFORT | 08JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718008 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | OEDEMA PERIPHERAL | 20JAN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718008 | Clinwrightinib 200 mg | INFECTIONS AND INFESTATIONS | HORDEOLUM | 16APR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718009 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | NAUSEA | 17SEP2022 | MODERATE | N | RECOVERED/RESOLVED |
| ONCO-EX-718009 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE PAIN | 15OCT2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718009 | Clinwrightinib 200 mg | CARDIAC DISORDERS | SINUS BRADYCARDIA | 28OCT2022 | SEVERE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718009 | Clinwrightinib 200 mg | SKIN AND SUBCUTANEOUS TISSUE DISORDERS | PRURITUS | 29OCT2022 | MODERATE | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718009 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 01NOV2022 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718009 | Clinwrightinib 200 mg | RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | COUGH | 27DEC2022 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718010 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | VOMITING | 31DEC2022 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-718010 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 29MAR2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718010 | Clinwrightinib 200 mg | INVESTIGATIONS | ELECTROCARDIOGRAM T WAVE INVERSION | 02JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718010 | Clinwrightinib 200 mg | VASCULAR DISORDERS | WOUND HAEMORRHAGE | 31JUL2023 | SEVERE | N | RECOVERED/RESOLVED |
| ONCO-EX-718011 | Standard of Care | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | SHOULDER PAIN | 16JUL2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718011 | Standard of Care | NERVOUS SYSTEM DISORDERS | PARKINSON'S DISEASE | 18NOV2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718013 | Clinwrightinib 200 mg | GASTROINTESTINAL DISORDERS | DIARRHOEA | 18FEB2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718013 | Clinwrightinib 200 mg | CARDIAC DISORDERS | ATRIOVENTRICULAR BLOCK SECOND DEGREE | 21JUN2023 | MILD | N | RECOVERED/RESOLVED |
| ONCO-EX-718013 | Clinwrightinib 200 mg | GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | APPLICATION SITE ERYTHEMA | 20JUL2023 | MILD | N | NOT RECOVERED/NOT RESOLVED |
| ONCO-EX-718013 | Clinwrightinib 200 mg | MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | MUSCLE SPASMS | 20JUL2023 | MILD | N | RECOVERED/RESOLVED |
Source: ADAE.
Program: l-16-2-7.sas
Program l-16-2-7.sas
Version 1, written from Clinwright's patterns, 2026-10-17, checks passed.
/*==== 00-header ====*/
/*----------------------------------------------------------------------------
Output : Listing 16.2.7 / Listing of Treatment-Emergent Adverse Events / Safety Analysis Set
Program : l-16-2-7.sas Reporting effort : CSR
ADaM : /work/adam (ADSL, ADLBC, ADLBH, ADVS, ADAE, ADEG, ADCM, ADMH, ADEX, ADRS, ADTR, ADTTE)
The header and the report step follow from the shell. The sections between
them make WORK.FINAL, one record per row of the table, in order:
_page the page (1 unless the output is paged); _pagelbl its heading or empty
_ord the row's order; _indent the label's indentation (0 = flush left)
_rowid the uuid of the shell row it shows (WORK._SHELL); one shell row may
have several (a category per value); a blank row's is blank-<n>
_kind label | stat | blank
rowlabel the row's label, as text
col1 Treatment (TRTA)
col2 System organ class (AEBODSYS)
col3 Preferred term (AEDECOD)
col4 Start date (ASTDT)
col5 Severity (AESEV)
col6 Serious (AESER)
col7 Outcome (AEOUT)
/work/_lib/clinwright.sas has %ls_bign, %ls_count, %ls_stats, %ls_npct, %ls_num.
----------------------------------------------------------------------------*/
libname adam "/work/adam" access=readonly;
%include "/work/_lib/clinwright.sas";
%ls_setup;
/*==== 10-data ====*/
/* Made from the output's analysis: the records of ADAE with TRTEMFL = 'Y' of the subjects of ADSL with SAFFL = 'Y', by USUBJID, ASTDT. */
data work._pop1; set adam.adsl(where=(saffl = 'Y')); keep usubjid; run;
proc sort data=work._pop1; by usubjid; run;
proc sort data=adam.adae(keep=usubjid trta saffl astdt aedecod aebodsys aesev aeser aeout trtemfl where=(TRTEMFL = 'Y')) out=work._rec; by usubjid; run;
data work._an; merge work._rec(in=_r) work._pop1(in=_p); by usubjid; if _r and _p; run;
proc sort data=work._an; by usubjid astdt; run;
data work.final;
length _pagelbl $200 _rowid $36 _kind $5 rowlabel col1 col2 col3 col4 col5 col6 col7 $200;
set work._an;
_page = 1; _pagelbl = ''; _indent = 0; _rowid = ''; _kind = 'stat';
rowlabel = strip(vvalue(usubjid));
col1 = strip(vvalue(trta));
col2 = strip(vvalue(aebodsys));
col3 = strip(vvalue(aedecod));
col4 = strip(vvalue(astdt));
col5 = strip(vvalue(aesev));
col6 = strip(vvalue(aeser));
col7 = strip(vvalue(aeout));
_ord = _n_;
keep _page _pagelbl _ord _indent _rowid _kind rowlabel col1 col2 col3 col4 col5 col6 col7;
run;
data work.final;
if _nobs = 0 then do;
_page = 1; _pagelbl = ''; _indent = 0; _rowid = ''; _kind = 'stat'; _ord = 1; rowlabel = 'No records to report.'; output;
end;
set work.final nobs=_nobs;
output;
run;
/*==== 90-report ====*/
/* 90-report: from the shell; the titles, columns, headers and footnotes are not changed here. */
%ls_final_check(columns=_page _pagelbl _ord _indent _rowid _kind rowlabel col1 col2 col3 col4 col5 col6 col7);
proc sort data=work.final out=work._report; by _page _ord; run;
data work._report;
set work._report;
/* Two spaces per step of indentation: the label column keeps leading spaces (asis=on). */
if _indent > 0 then rowlabel = repeat(' ', 2 * _indent - 1) || rowlabel;
run;
%let _lspaged = 0;
proc sql noprint; select count(*) into :_lspaged trimmed from work._report where _pagelbl ne ''; quit;
options orientation=landscape;
ods listing close;
ods rtf file="/work/out/l-16-2-7.rtf" style=journal;
title1 j=l "ONCO-EX" j=r "Page ~{thispage} of ~{lastpage}";
title2 j=c "Listing 16.2.7";
title3 j=c "Listing of Treatment-Emergent Adverse Events";
title4 j=c "Safety Analysis Set";
footnote1 j=l "Source: ADAE.";
footnote2 j=l "Program: l-16-2-7.sas";
%macro _ls_report;
proc report data=work._report nowd split='|' missing style(report)={width=100%};
column _page _pagelbl _ord _indent _kind rowlabel col1 col2 col3 col4 col5 col6 col7;
define _page / order order=internal noprint;
define _pagelbl / order noprint;
define _ord / order order=internal noprint;
define _indent / display noprint;
define _kind / display noprint;
define rowlabel / display "Subject" style(column)={cellwidth=12.5% asis=on} style(header)={just=l};
define col1 / display "Treatment" style(column)={cellwidth=12.5% just=c} style(header)={just=c};
define col2 / display "System organ class" style(column)={cellwidth=12.5% just=c} style(header)={just=c};
define col3 / display "Preferred term" style(column)={cellwidth=12.5% just=c} style(header)={just=c};
define col4 / display "Start date" style(column)={cellwidth=12.5% just=c} style(header)={just=c};
define col5 / display "Severity" style(column)={cellwidth=12.5% just=c} style(header)={just=c};
define col6 / display "Serious" style(column)={cellwidth=12.5% just=c} style(header)={just=c};
define col7 / display "Outcome" style(column)={cellwidth=12.5% just=c} style(header)={just=c};
%if &_lspaged > 0 %then %do;
compute before _pagelbl / style={just=l};
line _pagelbl $200.;
endcomp;
%end;
break after _page / page;
run;
%mend _ls_report;
%_ls_report;
ods rtf close;
ods listing;
%ls_final_export;